To compare safety of provided TI in combination with any other diabetic agents versus Anti-diabetic agents without TI (UC Group) in Type 1 or Type 2 diabetic subjects with Asthma or COPD with respect to lung function. [ Time Frame: 52 Weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Compare between the treatment groups the effect treatment: on Glycemic control, Frequency of pulmonary exacerbations, acute changes in lung function from after TI inhalation, Health related quality of life assessment. [ Time Frame: 52 Weeks ] [ Designated as safety issue: No ]

< 30% day-to-day variability in daily morning PEF during the 2-week run-in period

Significant improvement in pre- to postbronchodilator spirometry (defined as an increase from baseline of ≥ 12% and ≥ 200 mL in FEV1 or forced vital capacity [FVC]) at Screening/Visit 1 or documented significant improvement in pre- to postbronchodilator spirometry (as defined above) within past 12 months in subject's medical records or a documented positive methacholine challenge test within the past 12 months

COPD

Physician diagnosis of COPD (including emphysema and/or chronic bronchitis), history of dyspnea and/or intermittent or daily chronic cough with or without sputum production, not attributable to any other known cause

Former smoker (≥ 6 months since cessation) with smoking history of ≥ 10 pack years

Clinical diagnosis of Type1 or 2 diabetes mellitus for ≥ 12 months and no change in anti-diabetic regiment for at least 90-days prior to screening

BMI of, < 39 kg/m2

Urine cotinine level ≤ 100ng/dL

Clinical diagnosis of obstructive lung disease

HbA1C > 6.5% ≤ 11.5%

Exclusion Criteria:

History of pulmonary exacerbation within 8 weeks of screening/V1 or between V1 and V2

Use of systemic corticosteroids or antibiotics for respiratory illness within 8 weeks of screening/V1 OR between V1 and V2

Increase from baseline in the use of short-acting bronchodilator or short-acting anticholinergic agents, or the combination of the 2, by ≥6 puffs or ≥3 nebulizer treatments per day for ≥ 2 days

Treatment with supplemental oxygen therapy, room air oxygen saturation, 94% or history of intubation or ICU admission for respiratory illness in the past 5 yrs.

Greater than 2 hospitalizations or ER or urgent care visits or required >3 courses of systemic steroid in the past 12 months for respiratory illness

Use of Symlin® (pramlintide acetate) within the preceding 90 days

Two or more severe hypoglycemic episodes within 6 months of screening or episode of severe hypoglycemia between Screening and Baseline

Previous exposure to any inhaled insulin product

Currently using an insulin delivery pump

Requires significant change (define as initiation of a new medication or change in the dose or frequency of the controller medications) in the asthma or COPD therapeutic regimen within 8 weeks of Screening/Visit 1 (Week -4) or between Visit 1 and Baseline/Visit 2

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00642616